[CAS NO. 236395-14-5] Eslicarbazepine acetate

Name: Eslicarbazepine acetate
Brand: Arctom Scientific
SKU: HY-B0703

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [236395-14-5]

Distributor

Catalog

HY-B0703

Brand

MCE

CAS

236395-14-5

DESCRIPTION [236395-14-5]

Overview

MDL	-
Molecular Weight	296.32
Molecular Formula	C17H16N2O3
SMILES	O=C(N1C2=CC=CC=C2C[C@H](OC(C)=O)C3=CC=CC=C31)N

For research use only. We do not sell to patients.

Summary

Eslicarbazepine acetate (BIA 2-093), an antiepileptic drug, is a dual a dual Inhibitor of β-Secretase and voltage-gated sodium channel .

In Vivo

Eslicarbazepine acetate is an antiepileptic drug. It is a prodrug which is activated to eslicarbazepine (S-licarbazepine), an active metabolite of oxcarbazepine. Eslicarbazepine acetate is a prodrug for (S)-(+)-licarbazepine, the major active metabolite of oxcarbazepine. Its mechanism of action is therefore identical to that of oxcarbazepine. Eslicarbazepine acetate may not produce as high peak levels of (S)-(+)-licarbazepine immediately after dosing as does oxcarbazepine which could theoretically improve tolerability ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT02170649	Bial - Portela C S.A.	Epilepsy	September 2001	Phase 1
NCT02284854	Bial - Portela C S.A.	Epilepsy	July 2009	Phase 1
NCT02777671	Bial - Portela C S.A.	Epilepsy	October 2007	Phase 1
NCT02281448	Bial - Portela C S.A.	Epilepsy	March 2005	Phase 1
NCT01678976	Bial - Portela C S.A.	Epilepsy	March 2002	Phase 1
NCT02171195	Bial - Portela C S.A.	Epilepsy	July 2000	Phase 1
NCT02281591	Bial - Portela C S.A.	Epilepsy	June 2006	Phase 1
NCT02283814	Bial - Portela C S.A.	Epilepsy	January 2007	Phase 1
NCT00988429	Bial - Portela C S.A.\|Sunovion	Partial Epilepsy	December 2, 2008	Phase 3
NCT00957684	Bial - Portela C S.A.	Refractory Partial Epilepsy	July 2004	Phase 3
NCT02283801	Bial - Portela C S.A.	Epilepsy	November 2006	Phase 1
NCT00971295	Bial - Portela C S.A.	Neuropathic Pain	October 2007	Phase 1
NCT02288312	Bial - Portela C S.A.	Epilepsy	May 2007	Phase 1
NCT01129960	Bial - Portela C S.A.	Painful Diabetic Neuropathy	November 2010	Phase 3
NCT01587339	GlaxoSmithKline	Epilepsy	September 2010
NCT02287415	Bial - Portela C S.A.	Epilepsy	May 2002	Phase 1
NCT02172755	Bial - Portela C S.A.	Epilepsy	June 2002	Phase 1
NCT00900237	Bial - Portela C S.A.	Partial Epilepsy	November 2008	Phase 1
NCT01879345	Bial - Portela C S.A.	Epilepsy	October 2004	Phase 1
NCT02283840	Bial - Portela C S.A.	Epilepsy	May 2007	Phase 1
NCT01879332	Bial - Portela C S.A.	Epilepsy	December 2006	Phase 1
NCT03116321	Bial - Portela C S.A.	Epilepsy	December 3, 2016	Phase 1
NCT02283788	Bial - Portela C S.A.	Epilepsy	March 2007	Phase 1
NCT02283827	Bial - Portela C S.A.	Epilepsy	January 2007	Phase 1
NCT02284828	Bial - Portela C S.A.	Epilepsy	September 2007	Phase 1
NCT00866775	Sunovion	Epilepsy With Simple or Complex Partial Onset Seizures	April 2009	Phase 3
NCT02281526	Bial - Portela C S.A.	Epilepsy	May 2005	Phase 1
NCT00957372	Bial - Portela C S.A.	Partial Epilepsy	December 2004	Phase 3
NCT00981227	Bial - Portela C S.A.	Postherpetic Neuralgia	November 2007	Phase 2
NCT02172742	Bial - Portela C S.A.	Epilepsy	May 2002	Phase 1
NCT01091662	Sunovion	Epilepsy	June 2010	Phase 3
NCT01824602	Bial - Portela C S.A.	BIPOLAR I DISORDER	February 2006	Phase 2
NCT01162460	Bial - Portela C S.A.	Epilepsy	December 2010	Phase 3
NCT01527513	Bial - Portela C S.A.	Partial Epilepsy	August 2010	Phase 2
NCT02279667	Bial - Portela C S.A.	Epilepsy	February 2004	Phase 1
NCT01825837	Bial - Portela C S.A.	Bipolar I Disorder	March 2006	Phase 2
NCT00988156	Bial - Portela C S.A.	Partial Epilepsy in Children and Adolescents	December 7, 2007	Phase 3
NCT01878578	Bial - Portela C S.A.	Epilepsy	November 2002	Phase 1
NCT00980746	Bial - Portela C S.A.	Painful Diabetic Neuropathy	November 2007	Phase 2
NCT01124097	Bial - Portela C S.A.	Post Herpetic Neuralgia	September 2010	Phase 3
NCT02284880	Bial - Portela C S.A.	Epilepsy	October 2010	Phase 1
NCT02171234	Bial - Portela C S.A.	Epilepsy	February 2001	Phase 1
NCT02281422	Bial - Portela C S.A.	Epilepsy	March 2005	Phase 1
NCT02170077	Bial - Portela C S.A.	Epilepsy	April 2002	Phase 2
NCT01830400	Eisai Inc.	Partial Onset Seizures	April 2012
NCT00957047	Bial - Portela C S.A.	Partial Epilepsy	July 2004	Phase 3
NCT01822678	Bial - Portela C S.A.	Bipolar I Disorder	December 2005	Phase 2
NCT00910247	Sunovion	Epilepsy	August 2009	Phase 3
NCT02912364	Stanford University\|Sunovion	Epilepsy	July 2016	Phase 4
NCT02170064	Bial - Portela C S.A.	Epilepsy	June 2005	Phase 2
NCT03108729	Sunovion	Epilepsy	July 6, 2017	Phase 3
NCT01422720	Bial - Portela C S.A.	Epilepsy	April 2010	Phase 3
NCT01679002	Bial - Portela C S.A.	Epilepsy	October 2003	Phase 1
NCT03116828	Sunovion	Epilepsy With Partial On-set Seizures	July 7, 2017	Phase 4
NCT00987558	Bial - Portela C S.A.	Epilepsy	June 2009	Phase 1
NCT00898560	Bial - Portela C S.A.	Partial Epilepsy	September 2008	Phase 1

Appearance

Solid

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light, stored under nitrogen

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL ( 337.47 mM )

* "≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	3.3747 mL	16.8736 mL	33.7473 mL
5 mM	0.6749 mL	3.3747 mL	6.7495 mL
10 mM	0.3375 mL	1.6874 mL	3.3747 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

Solubility: ≥ 10 mg/mL (33.75 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)

Solubility: ≥ 10 mg/mL (33.75 mM); Clear solution
3.

Add each solvent one by one: 10% DMSO >> 90% corn oil

Solubility: ≥ 10 mg/mL (33.75 mM); Clear solution

* All of the co-solvents are available by MCE.

References

[1] Sibhghatulla Shaikh, et al. Aptiom (Eslicarbazepine Acetate) as a Dual Inhibitor of β-Secretase and Voltage-Gated Sodium Channel: Advancement in Alzheimer's Disease-Epilepsy Linkage via an Enzoinformatics Study. CNS & Neurological Disorders Drug Targets Volume 13 , Issue 7 , 2014.

Synonyms

5H-Dibenz[b,f]azepine-5-carboxamide, 10-(acetyloxy)-10,11-dihydro-, (10S)-

(10S)-10-(Acetyloxy)-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

BIA 2-093

(S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

(S)-10-Acetoxy-10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide

Eslicarbazepine acetate

Sep 0002093

Exelief

(S)-(-)-10-Acetoxy-10,11-dihydro-5H-dibenzo[b,f]azepine-5-carboxamide

Aptiom

(S)-5-Carbamoyl-10,11-dihydro-5H-dibenzo[b,f]azepin-10-yl acetate

Zebinix

Exalief